Denosumab Demonstrates Survival Benefit in Postmenopausal Women

Lauren M. Green @OncNurseEditor
Published: Wednesday, Dec 09, 2015

Although the FDA has approved adjuvant denosumab as a treatment to increase bone mass in patients on AI therapy who are at high risk for fracture, it’s typically used only for those with established osteoporosis. With these new data, Gnant said, denosumab should be offered to all postmenopausal women with HR-positive breast cancer on AIs, regardless of their bone health status:

“When I see a new patient next week, I will start her on the two subcutaneous injections every 6 months for 3 years.”


  1. Gnant M, Pfeiler G, Dubsky PC, et al. The impact of adjuvant denosumab on disease-free survival: results from 3425 postmenopausal patients of the ABCSG-18 trial. Presented at: 2015 San Antonio Breast Cancer Symposium; San Antonio, TX; December 8-12, 2015. Abstract S2-02.
  2. Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicenter, randomized, double-blind placebo-controlled trial. Lancet. 2015;386(9992):433-443.
  3. Early Breast Cancer Trialists Cooperative Group. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomized trials. Lancet. 2015;386(10001):1353-1361.

<<< View more from the 2015 San Antonio Breast Cancer Symposium

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication